Lexaria Bioscience (NASDAQ: LEXX, LEXXW) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve delivery of lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (“APIs”) into the bloodstream while speeding onset, increasing bioavailability and improving efficacy.
DehydraTECH’s ability to enhance delivery promotes healthier oral ingestion methods and increased effectiveness of fat-soluble active molecules. As demonstrated through in vivo, in vitro and human clinical testing, DehydraTECH enables fast-acting, less expensive and more effective oral drug delivery.
The company operates an in-house research laboratory and has continued to strengthen and broaden its DehydraTECH technology, initially developed in 2014. Lexaria holds an intellectual property portfolio consisting of 23 patents granted in over 40 countries with a combined population of 2.6 billion, as well as over 50 additional patents pending worldwide.
Lexaria licenses DehydraTECH to companies around the globe to offer consumers the best possible performance across an array of ingestible products. DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions. The company’s technology offers a delivery method that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effective ness of their own existing or planned new offerings.
Lexaria has licensed DehydraTECH to multiple companies, including for use in industries that produce cannabinoid beverages, edibles and oral products, as well as for a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products.
For more information, visit the company’s website at www.LexariaBioscience.com.
To learn more about Benzinga’s Small Cap Conference, visit: https://ibn.fm/BenzingaSmallCapDec2021
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, provides the online investment community with custom-built portals that include summaries on hundreds of presenting companies. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of various investor conferences.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
